Antineoplastic Systemic Enzyme Inhibitors/Carbamazepine Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Carbamazepine may speed up how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your cancer medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. September, 2023.
- 2.Cabometyx (cabozantinib) tablets, US prescribing information. Exelixis Inc. January, 2021.
- 3.Cometriq (cabozantinib) US prescribing information. Exelixix, Inc. January, 2020.
- 4.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company February, 2023.
- 5.Tarceva (erlotinib) US prescribing information. Genentech, Inc. October, 2016.
- 6.Iressa (gefitinib tablets) US prescribing information. AstraZeneca Pharmaceuticals LP April 7, 2004.
- 7.Imbruvica (ibrutinib) US Prescribing information. Pharmacyclics, Inc. August, 2022.
- 8.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline December, 2018.
- 9.Votrient (pazopanib) US prescribing information. GlaxoSmithKline August, 2020.
- 10.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation July, 2020.
- 11.Sutent (sunitinib malate) US prescribing information. Pfizer Inc. August, 2021.
- 12.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP October, 2018.
- 13.Abbas R, Boni J, Sonnichsen D. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther 2015 Mar;30(1):57-63.
- 14.Ohgami M, Kaburagi T, Kurosawa A, Homma M. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer. Lung Cancer 2016 Nov;101:9-10.
- 15.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 16.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and -drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.